Back to Peptides

Adipotide

Metabolic & Weight Loss

Adipotide is a targeted peptidomimetic agent designed to induce fat loss by selectively disrupting the vasculature of white adipose tissue. It functions by binding to prohibitin receptors on blood vessels supplying fat cells, triggering apoptosis and subsequent fat mass reduction. In preclinical trials, it has demonstrated significant reductions in body weight and improvements in insulin sensitivity. Due to its pro-apoptotic mechanism and potential renal toxicity, Adipotide is typically used in short-term cycles under clinical supervision.

Reconstitute
null mL BAC + 2mg vial
Daily Range
1–5 mg Subcutaneous (SQ)
daily
Standard Dose
3 mg
Cycle
4–8 weeks
then reassess
Adipotidepeptidomimeticobesityweight lossapoptosis

Dosing & Reconstitution Guide

In preclinical trials, Adipotide was administered subcutaneously at 0.25–0.5 mg/kg/day. These findings do not translate to approved human usage.

Standard / Gradual Approach

standard
PhaseDoseVolume
Week 10.25mg/kg
Week 20.5mg/kg
Week 31mg/kg
Week 41.5mg/kg

Protocol Summary

Subcutaneous (SQ): daily · Dose range 1–5 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Recommended frequency: Daily injection. Suggested cycle length: 2–4 weeks max due to potential renal and liver stress. Follow with a recovery period of at least 4–6 weeks. Avoid stacking with hepatotoxic or nephrotoxic agents during active cycle.

🧪 Quick Start

BAC Water
2 mL
Concentration
500 mcg/unit
Starting Dose
1mg/kg

Potential Benefits & Use Cases

Adipotide is not approved by the FDA and is intended solely for preclinical research.
Selectively induces fat loss by targeting adipose vasculature
Demonstrated significant weight loss in rhesus monkeys
Studied for visceral fat reduction and insulin sensitivity improvements
Shows potential for addressing obesity-related metabolic issues in animal models
Mechanism differs from hormonal appetite suppression
Clinical data Strong preclinical Limited data

Mechanism of Action

→Induces apoptosis in blood vessels of white adipose tissue
→Targets prohibitin complexes

Lifestyle & Optimization

timing

Daily subcutaneous injection. Short cycles of 2–4 weeks due to renal/liver stress.

diet

Maintain adequate protein consumption (0.8–1g per pound of body weight). Monitor caloric intake.

exercise

Moderate cardiovascular exercise 3–4 times weekly.

sleep

Sleep 7–9 hours nightly to support metabolic recovery.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese MonkeysReference
Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic PotentialReference

Side Effects & Safety

Common Side Effects

• Injection site reactions

Contraindications & Warnings

• Potential liver toxicity
• Renal impairment

Long-Term Safety Data

• Unknown

🧮 Dose Calculator

Concentration
10.0
mcg/unit
Draw Volume
50
units (0.500 mL)
For a 500 mcg dose, draw 50 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High bioavailability when administered subcutaneously as it directly targets adipose tissue.
Oral Administration
Not available orally due to poor bioavailability.
Half-Life
4 hours
Degradation
Primarily degraded in the liver.
Tissue Specificity
Affects primarily the vasculature of white adipose tissues.
⚗️

Peptide Details

Molecular Weight
2220
Formula
C111H204N36O28
Sequence
CKGGRAKDC
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
Store lyophilized powder in a cool, dark place at 2-8°C
Reconstituted (Mixed)
After reconstitution, store at 2-8°C and use within 28 days. Avoid repeated freeze-thaw cycles.